Cellectis quits CAR-Ts and pivots to ‘in vivo’ gene editing
Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
Read the full article on the original site.
Read Full Article